The abstract is read at the publisher; the summary is JClub's.
In Black participants with APOL1-mediated CKD in CRIC and SPRINT, renin-angiotensin system inhibitor use is linked to lower kidney-outcome risk across 0, 1, and 2 risk alleles (HRs 0.62, 0.68, 0.59).
- Why it matters: RAS inhibitors are standard for proteinuric CKD, but their kidney-outcome impact in Black individuals has been uncertain and may vary by APOL1 genotype and baseline albuminuria.
- What they did: Black participants with APOL1 genotyping on first-line antihypertensive therapy were analyzed in CRIC and SPRINT (n=3418; 62% from SPRINT) using Cox models with inverse probability of treatment weighting and marginal structural models.
- The result: The association was driven by albuminuric participants (two risk alleles: albuminuric HR 0.62 [0.41–0.93]; non-albuminuric HR 0.37 [0.13–1.08], imprecise), suggesting similar benefit across APOL1 genotypes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.